Diabetic foot ulcers (DFUs) remain a significant health concern worldwide, contributing to considerable morbidity, disability ...

BYD’s second shock announcement of the year could put others out of business, say these Financial Times writers.

Welcome to the Amprius Technologies Fourth Quarter and Full Year 2024 Earnings Conference Call. Joining us for today's presentation are the company's CEO, Dr. Kang Sun; and CFO, Sandra Wallach.

Previously reported MRD negative CR in 2 of 3 relapsed/refractory AML patients enrolled in first dose level and schedule of Phase 1 clinical ...

GeekWire Award finalists for Health Innovation of the Year are dominated by ventures that aim to outwit cancer with ...

Although cystic fibrosis is a single gene mutation, there are more than 1,000 different ways the CFTR gene can mutate in ...

Cellares’ Cell Shuttle performed all unit operations in an automated manner, including cell isolation, enrichment, gene ...

The Fidelis Partnership, a privately owned, Bermuda-domiciled managing general underwriter, has reported gross written ...

Researchers from the University of Bath have developed an irreversible inhibitor of the transcription factor cJun, which drives certain difficult-to-treat cancers.

As AstraZeneca awaits an FDA decision for its Daiichi Sankyo-partnered Datroway in EGFR-mutated non-small cell lung cancer ...

Mandimycin is structurally similar to the last-line-of-defense antifungal amphotericin B, another glycosylated polyene ...